South Korea
· Delayed Price · Currency is KRW T&R Biofab Statistics
Total Valuation
T&R Biofab has a market cap or net worth of KRW 126.05 billion. The enterprise value is 140.34 billion.
| Market Cap | 126.05B |
| Enterprise Value | 140.34B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
T&R Biofab has 21.55 million shares outstanding. The number of shares has increased by 1.43% in one year.
| Shares Outstanding | 21.55M |
| Shares Change (YoY) | +1.43% |
| Shares Change (QoQ) | +2.34% |
| Owned by Insiders (%) | 26.39% |
| Owned by Institutions (%) | 16.91% |
| Float | 15.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.34 |
| PB Ratio | 5.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.77 |
| EV / Sales | 28.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.26 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 160.82.
| Current Ratio | 0.94 |
| Quick Ratio | 0.72 |
| Debt / Equity | 160.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.43 |
| Interest Coverage | -11.96 |
Financial Efficiency
Return on equity (ROE) is -52.16% and return on invested capital (ROIC) is -15.86%.
| Return on Equity (ROE) | -52.16% |
| Return on Assets (ROA) | -12.87% |
| Return on Capital (ROIC) | -15.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -54.58% |
| 50-Day Moving Average | 6,263.00 |
| 200-Day Moving Average | 7,537.15 |
| Relative Strength Index (RSI) | 41.16 |
| Average Volume (20 Days) | 28,627 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, T&R Biofab had revenue of KRW 4.94 billion and -14.37 billion in losses. Loss per share was -671.96.
| Revenue | 4.94B |
| Gross Profit | 1.36B |
| Operating Income | -14.81B |
| Pretax Income | -14.37B |
| Net Income | -14.37B |
| EBITDA | -12.44B |
| EBIT | -14.81B |
| Loss Per Share | -671.96 |
Balance Sheet
The company has 22.60 billion in cash and 36.89 billion in debt, giving a net cash position of -14.29 billion or -663.32 per share.
| Cash & Cash Equivalents | 22.60B |
| Total Debt | 36.89B |
| Net Cash | -14.29B |
| Net Cash Per Share | -663.32 |
| Equity (Book Value) | 22.94B |
| Book Value Per Share | 1,055.95 |
| Working Capital | -2.04B |
Cash Flow
In the last 12 months, operating cash flow was -9.30 billion and capital expenditures -5.86 billion, giving a free cash flow of -15.16 billion.
| Operating Cash Flow | -9.30B |
| Capital Expenditures | -5.86B |
| Free Cash Flow | -15.16B |
| FCF Per Share | -703.56 |
Margins
Gross margin is 27.54%, with operating and profit margins of -300.05% and -291.04%.
| Gross Margin | 27.54% |
| Operating Margin | -300.05% |
| Pretax Margin | -291.04% |
| Profit Margin | -291.04% |
| EBITDA Margin | -251.90% |
| EBIT Margin | n/a |
| FCF Margin | -307.05% |
Dividends & Yields
T&R Biofab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.43% |
| Shareholder Yield | -1.43% |
| Earnings Yield | -11.49% |
| FCF Yield | -12.03% |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Apr 5, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |